In conclusion, PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy are effective, safe, and well-tolerated as first-line therapies for advanced ICC. The gene discussed is PDCD1; the disease is intrahepatic cholangiocarcinoma.